Navigation Links
Study Shows That Roche's Investigational Drug for Alzheimer's Disease Removes Amyloid Plaques From the Brain
Date:10/10/2011

BASEL, Switzerland, Oct. 10, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the publication of a study demonstrating that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer's disease. The study "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab" is published today in the October issue of Archives in Neurology.(1)

It is the first time that clinical data has been published for gantenerumab, an investigational compound with a mechanism of action targeted at the early stages of Alzheimer's disease.

Results from Phase I clinical trials and ex vivo studies demonstrated that gantenerumab treatment results in a dose-dependent reduction of brain amyloid, possibly through phagocytosis via brain microglial cells, whereas amyloid load increased in patients receiving placebo treatment.

"These results and especially the rapidity of the effects observed on amyloid removal are very encouraging and pave the way for the development of a novel treatment for Alzheimer's disease," said Luca Santarelli, Global Head of Roche Neuroscience Disease Translational Area. "Our approach is to utilize biomarkers to diagnose and treat the disease at a very early stage before significant damage to the brain has occurred."

Gantenerumab is an investigational fully human anti-amyloid beta monoclonal antibody designed to bind to amyloid plaques in the brain and remove them. It is hoped that this approach will slow progression of the disease, an outcome that cannot be achieved with currently approved treatments.

"Our objective was not only to demonstrate the effects of gantenerumab on brain amyloid, but also to start elucidating its mechanism of action," added Santarelli, "this is extremely important to fully understand the compound's therapeutic potential for Alzheimer's disease."

Since it is known that amyloid accumulate
'/>"/>

SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Hernia Publishes a Unique Three Year Pre-Clinical Study of absorbable TIGR® Matrix Surgical Mesh Versus a Permanent Mesh
2. Hologic Announces Six-year Follow-up Results from the MammoSite Targeted Breast Irradiation Registry Study
3. Bioness Inc. Announces Completion of Enrollment in Its FASTEST L300 Study
4. FDA CONSUMER HEALTH INFORMATION -- Foreign Exporters Study Food Safety Law
5. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
6. Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society
7. Study by Ocala Oncology/The US Oncology Network Shows Use of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Improves Overall Survival
8. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
9. Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients
10. To Succeed in Crowded Market, Diabetes Manufacturers Beginning Key Launch Tactics Earlier, Study Says
11. Swype Cold & Flu Shield Significantly Reduces Occurrence of Colds in Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... of the "Infectious Disease Diagnostics Market by Product, ... report to their offering. , The ... CAGR of 7.9% to reach $18,156.2 million by 2019 ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... Diagnostics Market by Allergen Source, Product & by End User ... The global allergy diagnostics market is valued ... at a CAGR of 12.67%, to reach $2,230.72 million by ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "X-Ray Detectors Market by Detector Type, Applications & by FPD ... their offering. , The X-ray detectors market ... technological advancements since its inception, such as a shift from ...
Breaking Medicine Technology:Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3Global X-Ray Detectors (Flat Panel, Computed Radiography, CCD, Line-Scan) Market - Forecast to 2019 2Global X-Ray Detectors (Flat Panel, Computed Radiography, CCD, Line-Scan) Market - Forecast to 2019 3
... , , ... KERX ) today announced results of the Open Label ... of elevated serum phosphorous levels, or hyperphosphatemia, in patients with ... in Taiwan, enrolled 29 of the 37 Taiwanese patients that ...
... , , , ... today announced results from a Phase II trial of regorafenib (BAY 73-4506), ... in a 31 percent partial response rate and 50 percent stabilization rate ... in an oral session at the joint 15th Congress of the European ...
Cached Medicine Technology:Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 2Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 3Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 4Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... 22, 2015 Compare-autoinsurance.org has released a new blog ... an auto insurance policy . , Some types of ... should check the newly released blog post to see if their ... dangerously damaged vehicles are some of the cars that cannot be ...
(Date:1/22/2015)... USA (PRWEB) January 22, 2015 State ... statewide data management system with support from GEOSYSTEMS, a ... The new solution will leverage Hexagon Geospatial’s ERDAS ... vector data as well as point clouds and documents. ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... DaVita,s Efforts in Corporate Social Responsibility and Support ... Calif., May 22 DaVita Inc. (NYSE: ... care services for those diagnosed with chronic kidney ... and marketing departments received eight Hermes Creative Awards, ...
... breast cancer had additional malignant tumors found only by ... Medical Center. , A total of 199 patients ... found additional, unsuspected cancers in the ipsilateral breast (the ... 16% of patients; we found cancers in the contralateral ...
... issued the,following press release: , ... flurry of panic about,the H1N1 (swine influenza). School ... even suggested closing the border with Mexico,where approximately three ... every day. The panic certainly was fueled by ...
... CyberKnife Centers Are Meeting Increasing Demand for ... TechnologiesSUNNYVALE, Calif., May 22 Accuray Incorporated ... leader in the field of radiosurgery, announced ... patient throughput using their recently installed, next ...
... Effort Addressing the Leading Cause of Maternal Mortality to ... Every year, more than half a million of the ... crisis that has seen little to no improvement over ... by Pathfinder International capitalized on groundbreaking new technologies in ...
... Reach $500 Million by 2014PRINCETON, N.J., May 22 ... federal funds next year and more than $500 million ... rules proposed to take effect in October, according to ... Economics department examined the impact of three provisions under ...
Cached Medicine News:Health News:DaVita Wins Eight Hermes Creative Awards Recognizing Excellence in Communications and Marketing 2Health News:DaVita Wins Eight Hermes Creative Awards Recognizing Excellence in Communications and Marketing 3Health News:H1N1: What You Should Know 2Health News:H1N1: What You Should Know 3Health News:Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife 2Health News:Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife 3Health News:Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife 4Health News:New Initiative Poised To Reduce Maternal Mortality Rates By More Than 25 Percent 2Health News:N.J. Hospitals Face $97 Million in Medicare Cuts 2Health News:N.J. Hospitals Face $97 Million in Medicare Cuts 3
BD Vacutainer® Fluoride Tubes - Plastic...
Inquire...
Inquire...
... The inner wall of the serum ... particles, these particles activate the coagulation process. ... gel in the base of the tube; ... barrier between the serum and the blood ...
Medicine Products: